瑞朗医药 (835600.OC)

+ 收藏

现金流量表(瑞朗医药)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年中报2023年年报2023年中报2022年年报2022年中报
上市前/上市后 上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表
一、经营活动产生的现金流量
 销售商品、提供劳务收到的现金(元) 702,294,481.991,408,134,582.81670,902,520.391,326,165,156.60693,302,612.15
 收到的税费返还(元) 1,731.019,287.61-3,899,735.023,820,264.86
 收到其他与经营活动有关的现金(元) 280,158.79797,540.678,300,646.044,505,887.432,701,760.22
 经营活动现金流入小计(元) 702,576,371.791,408,941,411.09679,203,166.431,334,570,779.05699,824,637.23
 购买商品、接受劳务支付的现金(元) 601,216,145.641,301,051,680.12583,307,558.641,289,065,737.84581,794,596.64
 支付给职工以及为职工支付的现金(元) 17,029,045.2237,173,106.9819,208,043.3831,801,029.6817,114,203.80
 支付的各项税费(元) 7,633,543.3011,035,998.466,642,194.079,653,228.686,370,350.18
 支付其他与经营活动有关的现金(元) 8,684,529.8526,471,779.8212,062,512.2717,378,799.7814,043,982.51
 经营活动现金流出小计(元) 634,563,264.011,375,732,565.38621,220,308.361,347,898,795.98619,323,133.13
 经营活动产生的现金流量净额(元) 68,013,107.7833,208,845.7157,982,858.07-13,328,016.9380,501,504.10
二、投资活动产生的现金流量
 购建固定资产、无形资产和其他长期资产支付的现金(元) 3,487,507.5971,522,818.8061,055,539.9099,859,443.4369,546,664.31
 投资活动现金流出小计(元) 3,487,507.5971,522,818.8061,055,539.9099,859,443.4369,546,664.31
 投资活动产生的现金流量净额(元) -3,487,507.59-71,522,818.80-61,055,539.90-99,859,443.43-69,546,664.31
三、筹资活动产生的现金流量
 吸收投资收到的现金(元) ---15,920,000.0015,920,000.00
 取得借款收到的现金(元) 302,730,508.32516,343,700.51287,576,266.85641,193,257.21291,361,523.43
 收到其他与筹资活动有关的现金(元) 27,718,878.08153,786,167.5937,605,247.8851,820,044.6118,228,508.09
 筹资活动现金流入小计(元) 330,449,386.40670,129,868.10325,181,514.73708,933,301.82325,510,031.52
 偿还债务支付的现金(元) 296,613,242.59526,248,402.48244,568,222.56532,277,517.98300,670,127.90
 分配股利、利润或偿付利息支付的现金(元) 19,725,245.3932,551,674.1021,611,540.7525,391,514.5117,190,610.34
 支付其他与筹资活动有关的现金(元) 90,273,623.3855,064,321.5927,643,636.7256,703,756.0030,880,954.52
 筹资活动现金流出小计(元) 406,612,111.36613,864,398.17293,823,400.03614,372,788.49348,741,692.76
 筹资活动产生的现金流量净额(元) -76,162,724.9656,265,469.9331,358,114.7094,560,513.33-23,231,661.24
五、现金及现金等价物净增加额(元) -11,637,124.7717,951,496.8428,285,432.87-18,626,947.03-12,276,821.45
 加:期初现金及现金等价物余额(元) 22,194,028.144,242,531.304,242,531.3022,869,478.33-
 期末现金及现金等价物余额(元) 10,556,903.3722,194,028.1432,527,964.174,242,531.30-12,276,821.45
补充资料:
 净利润(元) 3,630,115.919,716,203.553,230,728.0414,544,768.373,288,307.19
 资产减值准备(元) 101,817.66115,238.6798,577.01119,324.3990,736.67
 固定资产和投资性房地产折旧(元) 7,519,015.9414,948,198.217,441,335.132,829,242.581,157,307.12
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧(元) 7,519,015.9414,948,198.217,441,335.132,829,242.581,157,307.12
 无形资产摊销(元) 112,540.41238,626.91119,313.45238,626.91755,420.99
 长期待摊费用摊销(元) 90,853.08635,210.98---
 处置固定资产、无形资产和其他长期资产的损失(元) -90,744.3090,744.30--
 固定资产报废损失(元) 2,959.20----
 财务费用(元) 10,123,863.9221,584,176.0810,107,572.3716,981,033.817,678,859.70
 投资损失(元) 196,271.47126,158.26256,332.19--
 递延所得税(元) 100,109.55-149,585.3621,945.14-466,679.13-4,131.50
  其中:递延所得税资产减少(元) 637,228.63580,834.03838,770.46-1,259,541.61370,873.18
 递延所得税负债增加(元) -537,119.08-730,419.39-816,825.32792,862.48-375,004.68
 存货的减少(元) -24,617,194.43-28,256,949.29-33,897,129.56-20,921,423.8945,394,047.48
 经营性应收项目的减少(元) -18,274,751.5540,576,188.8030,712,367.06-123,132,513.0822,898,510.35
 经营性应付项目的增加(元) 88,706,040.33-27,277,128.9039,596,808.6994,593,739.77-1,016,935.94
 现金的期末余额(元) 10,556,903.3722,194,028.1432,527,964.174,242,531.3010,592,656.88
 减:现金的期初余额(元) 22,194,028.144,242,531.304,242,531.3022,869,478.3322,869,478.33
 现金及现金等价物的净增加额(元) -11,637,124.7717,951,496.8428,285,432.87-18,626,947.03-12,276,821.45
公告日期 2024-08-272024-04-192023-08-252023-04-262022-08-26
审计意见(境内) 标准无保留意见标准无保留意见
原始财报文件下载 下载财报(PDF)下载财报(PDF)下载财报(PDF)下载财报(PDF)下载财报(PDF)

前瞻产业研究院